- Home
- DRMA vs AYRO Comparison
DRMA vs AYRO Comparison
Compare DRMA & AYRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- AYRO
- Stock Information
- Founded
- DRMA 2014
- AYRO 2017
- Country
- DRMA United States
- AYRO United States
- Employees
- DRMA N/A
- AYRO N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- AYRO Telecommunications Equipment
- Sector
- DRMA Health Care
- AYRO Consumer Discretionary
- Exchange
- DRMA Nasdaq
- AYRO Nasdaq
- Market Cap
- DRMA 4.5M
- AYRO 3.7M
- IPO Year
- DRMA 2021
- AYRO N/A
- Fundamental
- Price
- DRMA $6.45
- AYRO $7.17
- Analyst Decision
- DRMA Strong Buy
- AYRO
- Analyst Count
- DRMA 1
- AYRO 0
- Target Price
- DRMA $3.00
- AYRO N/A
- AVG Volume (30 Days)
- DRMA 23.7K
- AYRO 38.5K
- Earning Date
- DRMA 08-11-2025
- AYRO 08-14-2025
- Dividend Yield
- DRMA N/A
- AYRO N/A
- EPS Growth
- DRMA N/A
- AYRO N/A
- EPS
- DRMA N/A
- AYRO N/A
- Revenue
- DRMA N/A
- AYRO $5,426.00
- Revenue This Year
- DRMA N/A
- AYRO N/A
- Revenue Next Year
- DRMA N/A
- AYRO N/A
- P/E Ratio
- DRMA N/A
- AYRO N/A
- Revenue Growth
- DRMA N/A
- AYRO N/A
- 52 Week Low
- DRMA $5.74
- AYRO $5.17
- 52 Week High
- DRMA $37.90
- AYRO $15.28
- Technical
- Relative Strength Index (RSI)
- DRMA 43.91
- AYRO 51.26
- Support Level
- DRMA $5.94
- AYRO $6.90
- Resistance Level
- DRMA $7.33
- AYRO $7.85
- Average True Range (ATR)
- DRMA 0.63
- AYRO 0.53
- MACD
- DRMA -0.05
- AYRO 0.07
- Stochastic Oscillator
- DRMA 27.68
- AYRO 49.43
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About AYRO AYRO Inc.
AYRO Inc designs and manufactures compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, focusing on the manufacturing and sales of environmentally-conscious, minimal-footprint EVs.